In what regulators called the latest advance in the development of personalized medicine, the U.S. Food and Drug Administration on Friday approved the first drug to treat cases of ovarian cancer linked to specific genetic mutations.. The drug, made by AstraZeneca PLC, was approved for women with defective genes, known as BRCA1 and BRCA2, who have advanced ovarian cancer. The mutations, first discovered in the mid-1990s, are linked to as many as 15% of all ovarian cancers and up to 10% of all breast cancers. Last year, actress...
  